Graph showing the adjusted mean change in EQ-VAS from baseline at IA-2 in the safety analysis dataset.

Figure 7Adjusted Mean Change From Baseline in EQ-VAS (IA-2, Safety Analysis Dataset)

EOT = end of treatment; EQ-VAS = EQ-5D-5L visual analogue scale; IA-2 = second interim analysis; SUVF: survival follow-up; WX = week X.

Note: Data for the adjusted mean and 95% CI are derived from mixed model repeated measures with week of visit and ECOG Performance Status as factors and baseline score as continuous covariate as well as an unstructured covariance structure.

From: Clinical Review

Cover of Dostarlimab (Jemperli)
Dostarlimab (Jemperli): CADTH Reimbursement Review: Therapeutic area: Endometrial cancer [Internet].
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.